WGU D027 Study Guide Graded A 100% Verified
Autosomal Dominant - 1 parent has, 50% change of child having Autosomal Recessive - Both parents are carriers, 25% change of child having, 50% chance child is a carrier. Cystic Fibrosis - affects pancreas causing secretions in lungs 21st Trisomy - Down Syndrome Klinefelter Syndrome (XXY) - male has extra X, female like qualities Turner Syndrome - Missing X in females Alpha Thalassemia - inherited blood disorder; mild to severe anemia Beta Thallasemia - low hemoglobin; contraindicated medication ferrous sulfate Prevalence Risk - proportion of the population affected at a certain time Incidence rate - number of new cases divided by population Innate immunity - inflammation; increased vascular permeability B&T lymphocytes - immune response primary malignant tumor - lack of organization of cells glucocorticoids - used in combination with other agent to treat lymphoid tissue (leukemia). glucocorticoids are directly toxic to lymphoid tissues. Selective estrogen receptor modulators (SERM) - for hormone receptor positive and advanced breast cancer. (Tamoxifin reduces risk and recurrence risk) Heart failure - impairment of the ventricle to fill with or eject blood; heart cannot meet metabolic need of the body. CHF - heart cannot keep up with metabolic needs; volume overload in pulmonary area Left Ventricular Dysfunction - reduced ejection fraction; ventricle having issue ejecting blood. normal ejection fraction - 55 - 60 % (blood pumped out with each heartbeat) Ejection fraction of 50% - reduced or preserved? - preserved Diastolic CHF - preserved ejection fraction, problem is with filling Systolic CHF - reduced ejection fraction, problem is with ejecting Left sided CHF - pulmonary (JVD, fluid volume overload, rails, S-3 murmurs) ** #1 cause of Right sided CHF BNP - gold standard lab test to diagnose CHF Echocardiogram - Diagnostic tool, evaluates heart structure and function At Risk for HF - Stage A - no structural heart disease or symptoms of heart failure Stage A HF co-morbidities - htn, atherosclerotic disease, diabetes, metabolic syndrome, patients using cardiotoxins with family history Therapy goals of stage A HF - treat htn, encourage smoking cessation, encourage regular exercise, treat lipid disorders, discourage alcohol intake/drug use, control metabolic syndrome Meds: ACEI or Angiotensin II RB for vascular disease or diabetes (avapro, losartan, benicar, diovan, etc) At Risk for HF - Stage B - structural heart disease but no symptoms of heart failure Stage B HF co-morbidities - previous MI, LV remodeling with LV hypertrophy and low EF, asymptomatic valvular disease Therapy goals of Stage B HF - Meds: ACEI or ARB, Beta-blockers, inplantable defibrillators Stage C heart failure - structural heart disease with prior or current symptoms of HF Presentation of Stage C HF - known structural heart disease and shortness of breath and fatigue, reduced exercise tolerance Therapy for Stage C HF - dietary salt restriction, MEDS: diuretic, ACEI, beta blockers. Some patients: aldosterone antagonist, ARBs, digitalis, hydralazine/nitrates, biventricular pacing, inplantable defibrillators Stage D heart failure - refractory HF requiring specialized interventions
Documentinformatie
- Geüpload op
- 26 mei 2023
- Aantal pagina's
- 11
- Geschreven in
- 2022/2023
- Type
- Tentamen (uitwerkingen)
- Bevat
- Vragen en antwoorden